Diagnostic Considerations

Other problems to consider in the differential diagnosis of avascular necrosis include the following:

Inflammatory synovitis
Complex regional pain syndrome
Osteoarthritis
Soft tissue trauma (eg, labral tear)
Osteomyelitis
Neoplastic bone conditions

Differential Diagnoses

Workup

Matthews AH, Davis DD, Fish MJ, Stitson D. Avascular Necrosis. 2022 Jan. [QxMD MEDLINE Link]. [Full Text].
Bose VC, Baruah BD. Resurfacing arthroplasty of the hip for avascular necrosis of the femoral head: a minimum follow-up of four years. J Bone Joint Surg Br. 2010 Jul. 92(7):922-8. [QxMD MEDLINE Link].
Aaron RK, Voisinet A, Racine J, Ali Y, Feller ER. Corticosteroid-associated avascular necrosis: dose relationships and early diagnosis. Ann N Y Acad Sci. 2011 Dec. 1240(1):38-46. [QxMD MEDLINE Link].
Enright H, Haake R, Weisdorf D. Avascular necrosis of bone: a common serious complication of allogeneic bone marrow transplantation. Am J Med. 1990 Dec. 89(6):733-8. [QxMD MEDLINE Link].
Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006 May 16. 144(10):753-61. [QxMD MEDLINE Link].
Dodson TB. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009 May. 67(5 Suppl):44-52. [QxMD MEDLINE Link].
Qi WX, Tang LN, He AN, Yao Y, Shen Z. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 2014 Apr. 19(2):403-10. [QxMD MEDLINE Link].
Shah KN, Racine J, Jones LC, Aaron RK. Pathophysiology and Risk Factors for Osteonecrosis. Current Reviews in Musculoskeletal Medicine. Sept 2015. 8(3): 201–209:[QxMD MEDLINE Link]. [Full Text].
Diz P, López-Cedrún JL, Arenaz J, Scully C. Denosumab-related osteonecrosis of the jaw. J Am Dent Assoc. 2012 Sep. 143(9):981-4. [QxMD MEDLINE Link].
Kawai K, Tamaki A, Hirohata K. Steroid-induced accumulation of lipid in the osteocytes of the rabbit femoral head. A histochemical and electron microscopic study. J Bone Joint Surg Am. 1985 Jun. 67(5):755-63. [QxMD MEDLINE Link].
Wang GJ, Sweet DE, Reger SI, et al. Fat-cell changes as a mechanism of avascular necrosis of the femoral head in cortisone-treated rabbits. J Bone Joint Surg Am. 1977 Sep. 59(6):729-35. [QxMD MEDLINE Link].
Assouline-Dayan Y, Chang C, Greenspan A, et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002 Oct. 32(2):94-124. [QxMD MEDLINE Link].
Bachiller FG, Caballer AP, Portal LF. Avascular necrosis of the femoral head after femoral neck fracture. Clin Orthop Relat Res. 2002 Jun. 87-109. [QxMD MEDLINE Link].
Lawson-Ayayi S, Bonnet F, Bernardin E, et al. Avascular necrosis in HIV-infected patients: a case-control study from the Aquitaine Cohort, 1997-2002, France. Clin Infect Dis. 2005 Apr 15. 40(8):1188-93. [QxMD MEDLINE Link].
Mehta P, Nelson M, Brand A, Boag F. Avascular necrosis in HIV. Rheumatol Int. 2013 Jan. 33(1):235-8. [QxMD MEDLINE Link].
Hasse B, Ledergerber B, Egger M, Flepp M, Bachmann S, Bernasconi E, et al. Antiretroviral treatment and osteonecrosis in patients of the Swiss HIV Cohort Study: a nested case-control study. AIDS Res Hum Retroviruses. 2004 Sep. 20(9):909-15. [QxMD MEDLINE Link].
Felten R, Perrin P, Caillard S, Moulin B, Javier RM. Avascular osteonecrosis in kidney transplant recipients: Risk factors in a recent cohort study and evaluation of the role of secondary hyperparathyroidism. PLoS One. 2019. 14 (2):e0212931. [QxMD MEDLINE Link]. [Full Text].
Fink JC, Leisenring WM, Sullivan KM, et al. Avascular necrosis following bone marrow transplantation: a case-control study. Bone. 1998 Jan. 22(1):67-71. [QxMD MEDLINE Link].
Chiu HY, Wang IT, Huang WF, Tsai YW, Shiu MN, Tsai TF. Increased risk of avascular necrosis in patients with psoriatic disease: A nationwide population-based matched cohort study. J Am Acad Dermatol. 2017 May. 76 (5):903-910.e1. [QxMD MEDLINE Link].
Rolston VS, Patel AV, Learch TJ, Li D, Karayev D, Williams C, et al. Prevalence and Associations of Avascular Necrosis of the Hip in a Large Well-characterized Cohort of Patients With Inflammatory Bowel Disease. J Clin Rheumatol. 2018 May 24. [QxMD MEDLINE Link].
Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. 2009 Mar. 36(3):478-90. [QxMD MEDLINE Link].
Steffen RT, Athanasou NA, Gill HS, Murray DW. Avascular necrosis associated with fracture of the femoral neck after hip resurfacing: histological assessment of femoral bone from retrieval specimens. J Bone Joint Surg Br. 2010 Jun. 92(6):787-93. [QxMD MEDLINE Link].
Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. 2005 Feb. 34(2):120-3. [QxMD MEDLINE Link].
Ninomiya S. An epidemiological survey of idiopathic avascular necrosis of the femoral head in Japan. Annual Report of Japanese Investigation Committee for Intractable Disease. 1989.
Goker B, Block JA. Risk of contralateral avascular necrosis (AVN) after total hip arthroplasty (THA) for non-traumatic AVN. Rheumatol Int. 2006 Jan. 26(3):215-9. [QxMD MEDLINE Link].
Lovecchio FC, Manalo JP, Demzik A, Sahota S, Beal M, Manning D. Avascular Necrosis Is Associated With Increased Transfusions and Readmission Following Primary Total Hip Arthroplasty. Orthopedics. 2017 May 1. 40 (3):171-176. [QxMD MEDLINE Link].
[Guideline] Expert Panel on Musculoskeletal Imaging: Ha AS, Chang EY, Bartolotta RJ, et al. ACR Appropriateness Criteria® Osteonecrosis. American College of Radiology. Available at https://acsearch.acr.org/docs/69420/Narrative/. Revised 2022; Accessed: August 13, 2022.
Staging of Avascular Necrosis. www.OrthopaedicsOne.com. Available at http://www.orthopaedicsone.com/display/Main/Staging+of+Avascular+Necrosis. February 22, 2009; Accessed: August 19, 2022.
[Guideline] Murphey MD, Roberts CC, Bencardino JT, Appel M, Arnold E, Chang EY, et al. ACR Appropriateness Criteria Osteonecrosis of the Hip. J Am Coll Radiol. 2016 Feb. 13 (2):147-55. [QxMD MEDLINE Link].
Ng FH, Lai TKB, Lam SY, Pan NY, Luk WH. Hybrid Magnetic Resonance Imaging with Single Photon Emission Computed Tomography/Computed Tomography Bone Scan for Diagnosis Of Avascular Necrosis of Femoral Head. J Clin Imaging Sci. 2021. 11:2. [QxMD MEDLINE Link]. [Full Text].
Iqbal B, Currie G. Value of SPECT/CT in the diagnosis of avascular necrosis of the head of femur: A meta-analysis. Radiography (Lond). 2022 May. 28 (2):560-564. [QxMD MEDLINE Link].
Luo RB, Lin T, Zhong HM, Yan SG, Wang JA. Evidence for using alendronate to treat adult avascular necrosis of the femoral head: a systematic review. Med Sci Monit. 2014 Nov 26. 20:2439-47. [QxMD MEDLINE Link].
Claßen T, Becker A, Landgraeber S, Haversath M, Li X, Zilkens C, et al. Long-term Clinical Results after Iloprost Treatment for Bone Marrow Edema and Avascular Necrosis. Orthop Rev (Pavia). 2016 Mar 21. 8 (1):6150. [QxMD MEDLINE Link]. [Full Text].
Pilge H, Bittersohl B, Schneppendahl J, Hesper T, Zilkens C, Ruppert M, et al. Bone Marrow Aspirate Concentrate in Combination With Intravenous Iloprost Increases Bone Healing in Patients With Avascular Necrosis of the Femoral Head: A Matched Pair Analysis. Orthop Rev (Pavia). 2016 Nov 17. 8 (4):6902. [QxMD MEDLINE Link]. [Full Text].
Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop. 2001 May. (386):173-8. [QxMD MEDLINE Link].
Wang CJ, Cheng JH, Huang CC, Yip HK, Russo S. Extracorporeal shockwave therapy for avascular necrosis of femoral head. Int J Surg. 2015 Dec. 24 (Pt B):184-7. [QxMD MEDLINE Link].
Gao F, Sun W, Li Z, Guo W, Wang W, Cheng L, et al. High-Energy Extracorporeal Shock Wave for Early Stage Osteonecrosis of the Femoral Head: A Single-Center Case Series. Evid Based Complement Alternat Med. 2015. 2015:468090. [QxMD MEDLINE Link].
Mathieu D, Marroni A, Kot J. Tenth European Consensus Conference on Hyperbaric Medicine: recommendations for accepted and non-accepted clinical indications and practice of hyperbaric oxygen treatment. Diving Hyperb Med. 2017 Mar. 47 (1):24-32. [QxMD MEDLINE Link]. [Full Text].
Bosco G, Vezzani G, Mrakic Sposta S, Rizzato A, Enten G, Abou-Samra A, et al. Hyperbaric oxygen therapy ameliorates osteonecrosis in patients by modulating inflammation and oxidative stress. J Enzyme Inhib Med Chem. 2018 Dec. 33 (1):1501-1505. [QxMD MEDLINE Link]. [Full Text].
Ceponis P, Keilman C, Guerry C, Freiberger JJ. Hyperbaric oxygen therapy and osteonecrosis. Oral Dis. 2017 Mar. 23 (2):141-151. [QxMD MEDLINE Link].
Freiberger JJ. Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009 May. 67(5 Suppl):96-106. [QxMD MEDLINE Link].
Van Laere C, Mulier M, Simon JP, et al. Core decompression for avascular necrosis of the femoral head. Acta Orthop Belg. 1998 Sep. 64(3):269-72. [QxMD MEDLINE Link].
Aldridge JM 3rd, Urbaniak JR. Avascular necrosis of the femoral head: role of vascularized bone grafts. Orthop Clin North Am. 2007 Jan. 38(1):13-22, v. [QxMD MEDLINE Link].
Hasegawa Y, Iwata H, Torii S, et al. Vascularized pedicle bone-grafting for nontraumatic avascular necrosis of the femoral head. A 5- to 11-year follow-up. Arch Orthop Trauma Surg. 1997. 116(5):251-8. [QxMD MEDLINE Link].
Urbaniak JR, Coogan PG, Gunneson EB, et al. Treatment of osteonecrosis of the femoral head with free vascularized fibular grafting. A long-term follow-up study of one hundred and three hips. J Bone Joint Surg Am. 1995 May. 77(5):681-94. [QxMD MEDLINE Link].
Zuo W, Sun W, Zhao D, Gao F, Su Y, Li Z. Investigating Clinical Failure of Bone Grafting through a Window at the Femoral Head Neck Junction Surgery for the Treatment of Osteonecrosis of the Femoral Head. PLoS One. 2016. 11 (6):e0156903. [QxMD MEDLINE Link]. [Full Text].
Sugano N, Takaoka K, Ohzono K, et al. Rotational osteotomy for non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg Br. 1992 Sep. 74(5):734-9. [QxMD MEDLINE Link].
Dudkiewicz I, Covo A, Salai M, et al. Total hip arthroplasty after avascular necrosis of the femoral head: does etiology affect the results?. Arch Orthop Trauma Surg. 2004 Mar. 124(2):82-5. [QxMD MEDLINE Link].
Cheung KW, Chiu KH, Chung KY. Long-term result of cementless femoral stem in avascular necrosis of the hip. Hip Int. 2014 Sep 1. [QxMD MEDLINE Link].
Gangji V, Hauzeur JP. Cellular-based therapy for osteonecrosis. Orthop Clin North Am. 2009 Apr. 40(2):213-21. [QxMD MEDLINE Link].
Lau RL, Perruccio AV, Evans HM, Mahomed SR, Mahomed NN, Gandhi R. Stem cell therapy for the treatment of early stage avascular necrosis of the femoral head: a systematic review. BMC Musculoskelet Disord. 2014 May 16. 15:156. [QxMD MEDLINE Link]. [Full Text].
Hernigou P, Trousselier M, Roubineau F, Bouthors C, Chevallier N, Rouard H, et al. Stem Cell Therapy for the Treatment of Hip Osteonecrosis: A 30-Year Review of Progress. Clin Orthop Surg. 2016 Mar. 8 (1):1-8. [QxMD MEDLINE Link]. [Full Text].
Piuzzi NS, Chahla J, Schrock JB, LaPrade RF, Pascual-Garrido C, Mont MA, et al. Evidence for the Use of Cell-Based Therapy for the Treatment of Osteonecrosis of the Femoral Head: A Systematic Review of the Literature. J Arthroplasty. 2017 May. 32 (5):1698-1708. [QxMD MEDLINE Link].
Hernigou P, Dubory A, Homma Y, Guissou I, Flouzat Lachaniette CH, Chevallier N, et al. Cell therapy versus simultaneous contralateral decompression in symptomatic corticosteroid osteonecrosis: a thirty year follow-up prospective randomized study of one hundred and twenty five adult patients. Int Orthop. 2018 May 9. [QxMD MEDLINE Link].
Houdek MT, Wyles CC, Collins MS, Howe BM, Terzic A, Behfar A, et al. Stem Cells Combined With Platelet-rich Plasma Effectively Treat Corticosteroid-induced Osteonecrosis of the Hip: A Prospective Study. Clin Orthop Relat Res. 2018 Feb. 476 (2):388-397. [QxMD MEDLINE Link].
Im GI. Stem Cell Therapy in Osteonecrosis of the Femoral Head. Hip Pelvis. 2018 Sep. 30 (3):135-137. [QxMD MEDLINE Link]. [Full Text].
Han J, Gao F, Li Y, Ma J, Sun W, Shi L, et al. The Use of Platelet-Rich Plasma for the Treatment of Osteonecrosis of the Femoral Head: A Systematic Review. Biomed Res Int. 2020. 2020:2642439. [QxMD MEDLINE Link]. [Full Text].
Ristow JJ, Ellison CM, Mickschl DJ, Berg KC, Haidet KC, Gray JR, et al. Outcomes of shoulder replacement in humeral head avascular necrosis. J Shoulder Elbow Surg. 2018 Sep 14. [QxMD MEDLINE Link].
van den Blink QU, Garcez K, Henson CC, Davidson SE, Higham CE. Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis associated with pelvic radiotherapy in adults. Cochrane Database Syst Rev. 2018 Apr 23. 4:CD010604. [QxMD MEDLINE Link].

Media Gallery

Avascular necrosis in the femoral head resulting from corticosteroid therapy.
Avascular necrosis of the shoulder showing subchondral radiolucent lines (crescent sign).
Avascular necrosis of both femoral heads. This T1-weighted image shows decreased signal intensity in both femoral heads.
MRI of the distal femur and proximal tibia. This T2-weighted image shows increased signal intensity in the marrow.

of 4

Staging of Avascular Necrosis

Staging of Avascular Necrosis

Stage	Clinical and Laboratory Findings
Stage 0	Patient is asymptomatic. Radiography findings are normal. Histology findings demonstrate osteonecrosis.
Stage I	Patient may or may not be symptomatic. Radiography and CT scan findings are unremarkable. AVN is considered likely based on MRI and bone scan results (may be subclassified by extent of involvement [see below]). Histology findings are abnormal.
Stage II	Patient is symptomatic. Plain radiography findings are abnormal and include osteopenia, osteosclerosis, or cysts. Subchondral radiolucency is absent. MRI findings are diagnostic.
Stage III	Patient is symptomatic. Radiographic findings include subchondral lucency (crescent sign) and subchondral collapse. Shape of the femoral head is generally preserved on radiographs and CT scans. Subclassification depends on the extent of crescent, as follows: Stage IIIa: Crescent is less than 15% of the articular surface. Stage IIIb: Crescent is 15-30% of the articular surface. Stage IIIc: Crescent is more than 30% of the articular surface.
Stage IV	Flattening or collapse of femoral head is present. Joint space may be irregular. CT scanning is more sensitive than radiography. Subclassification depends on the extent of collapsed surface, as follows: Stage IVa: Less than 15% of surface is collapsed. Stage IVb: Approximately 15-30% of surface is collapsed. Stage IVc: More than 30% of surface is collapsed.
Stage V	Radiography findings include narrowing of the joint space, osteoarthritis with sclerosis of acetabulum, and marginal osteophytes.
Stage VI	Findings include extensive destruction of the femoral head and joint.

Back to List

Author

Sunny B Patel, MD Chief Fellow, Department of Rheumatology, LSU Health Sciences Center

Sunny B Patel, MD is a member of the following medical societies: American College of Physicians, American College of Rheumatology, Louisiana State Medical Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Lawrence H Brent, MD Associate Professor of Medicine, Sidney Kimmel Medical College of Thomas Jefferson University; Chair, Program Director, Department of Medicine, Division of Rheumatology, Albert Einstein Medical Center

Lawrence H Brent, MD is a member of the following medical societies: American Association for the Advancement of Science, American Association of Immunologists, American College of Physicians, American College of Rheumatology

Disclosure: Stock ownership for: Johnson & Johnson.

Chief Editor

Herbert S Diamond, MD Visiting Professor of Medicine, Division of Rheumatology, State University of New York Downstate Medical Center; Chairman Emeritus, Department of Internal Medicine, Western Pennsylvania Hospital

Herbert S Diamond, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American College of Rheumatology, American Medical Association, Phi Beta Kappa

Disclosure: Nothing to disclose.

Additional Contributors

Bryan L Martin, DO Associate Dean for Graduate Medical Education, Designated Institutional Official, Associate Medical Director, Director, Allergy Immunology Program, Professor of Medicine and Pediatrics, Ohio State University College of Medicine

Bryan L Martin, DO is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American College of Allergy, Asthma and Immunology, American College of Osteopathic Internists, American College of Physicians, American Medical Association, American Osteopathic Association

Disclosure: Nothing to disclose.

Richa Dhawan, MD, CCD Associate Professor, Director of Osteoporosis Clinic, Center of Excellence for Arthritis and Rheumatology, Louisiana State University Health Science Center at Shreveport

Richa Dhawan, MD, CCD is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine, American College of Rheumatology, American Association of Physicians of Indian Origin

Disclosure: Nothing to disclose.

Jeanne K Tofferi, MD, MPH, FACP Assistant Chief, Department of Rheumatology, Walter Reed Army Medical Center

Jeanne K Tofferi, MD, MPH, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians

Disclosure: Nothing to disclose.

Acknowledgements

William Gilliland, MD, MPHE, FACP, FACR Staff Rheumatologist, Walter Reed Army Medical Center; Professor of Medicine, Assistant Dean of Curriculum, Uniformed Services University of the Health Sciences

Disclosure: Nothing to disclose.